BAEUERLE P A ET AL: "BiTE: a new class of antibodies that recruit T-cells", DRUGS OF THE FUTURE, vol. 33, no. 2, February 2008 (2008-02), pages 137-147, XP002667644, ISSN: 0377-8282 (B1)

WO-A1-2012/055961 (B2)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2009 (2009-11), NAGORSEN DIRK ET AL: "Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 mu g/m(2)/d of BiTE (R) Antibody Blinatumomab.", XP002668994, Database accession no. PREV201000353716 & NAGORSEN DIRK ET AL: BLOOD, vol. 114, no. 22, November 2009 (2009-11), page 1066, 51ST ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 05 -08, 2009 -& Nagorsen et al.: "Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients treated with 60 microg/m²/d of BiTE® Antibody Blinatumomab", Micromet - ASH Poster , 7 December 2009 (2009-12-07), XP002667643, Retrieved from the Internet: URL:http://www.micromet.com/Assets/ASH_pos ter_final_Dec_7_2009.aspx [retrieved on 2012-01-19] (B1)

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2010 (2010-11), VIARDOT ANDREAS ET AL: "Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 mu g/m(2)/d Is Tolerable and Highly Effective", XP002667646, Database accession no. PREV201100425423 & BLOOD, vol. 116, no. 21, November 2010 (2010-11), pages 1186-1187, 52ND ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ORLANDO, FL, USA; DECEMBER 04 -07, 2010 ISSN: 0006-4971(print) -& Viardot et al.: "Treatment of Patients With Non-Hodgkin Lymphoma With CD19/CD3Bispecific Antibody Blinatumomab (MT103)", Micromet , 6 December 2010 (2010-12-06), XP002667647, Retrieved from the Internet: URL:http://www.micromet.com/Assets/Microme t_Viardot_poster_6DEC2010.aspx [retrieved on 2012-01-19] (B1)

DIRK NAGORSEN ET AL: "Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab", LEUKEMIA AND LYMPHOMA, vol. 50, no. 6, 1 January 2009 (2009-01-01), pages 886-891, XP008128752, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH ISSN: 1042-8194, DOI: 10.1080/10428190902943077 (B1)

GOEBELER M ET AL: "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, vol. 95, no. Suppl. 2, 10 June 2010 (2010-06-10), - 13 June 2010 (2010-06-13), page 230, XP002667641, & 15TH ANNUAL MEETING OF THE EUROPEAN-HEMATOLOGY-ASSOCIATION; BARCELONA, SPAIN (B1)

HOFFMANN PATRICK ET AL: "Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct", INTERNATIONAL JOURNAL OF CANCER, vol. 115, no. 1, 20 May 2005 (2005-05-20), pages 98-104, XP002335808, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY ISSN: 0020-7136, DOI: 10.1002/IJC.20908 (B1)

R. Bargou: "1Blinatumomab (CD3/CD19 BiTE antibody) results in a high response rate in patients with relapsed non-hodgkin lymphoma (NHL) including MCL and DLBCL", , June 2011 (2011-06), XP002667645, 11th International Conference on Malignant Lymphoma, Lugano Switzerland, June 15-18, 2011 Retrieved from the Internet: URL:http://www.micromet.com/Assets/FN_Micr omet_ICML-NHL-Oral-15June.aspx [retrieved on 2012-01-18] (B1)

WO-A1-2007/068354 (B1)

WO-A1-2011/051307 (B1)

WO-A1-99/54440 (B1)

WOLF ET AL: "BiTEs: bispecific antibody constructs with unique anti-tumor activity", DRUG DISCOVERY TODAY, vol. 10, no. 18, 15 September 2005 (2005-09-15), pages 1237-1244, XP005103829, ELSEVIER, RAHWAY, NJ, US ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03554-3 (B1)

ALLEN SHIH et al.: "Role of Corticosteroids in Palliative Care", Journal of Pain & Palliative Care Pharmacotherapy, vol. 21, no. 4, 2007, pages 69-76, (B2)

GOEBELER et al.: "CD3/CD19 BISPECIFIC BITE (R) ANTIBODY BLINATUMOMAB TREATMENT OF NON-HODGKIN LYMPHOMA (NHL) PATIENTS: 60 mu G/M-2/D BY CONTINUOUS INFUSION IS TOLERABLE AND RESULTS IN DURABLE RESPONSES", HAEMATOLOGICA, vol. 95, no. Suppl 2, 10 June 2010 (2010-06-10), page 230, (B2)

KLINGER, MATTHIAS: "Wirkmechanismus des bispezifischen anti- CD 19 x anti- CD 3 BiTE- Antikorpers MT103 in Patienten mit rezidivem indolenten B-Zell-Non-Hodgkin-Lymphom", dissertation (doctor's thesis, 2009, (B2)

US-A1- 2007 224 191 (B2)

VIARDOT A. et al.: "Treatment of patients with non-hodgkin lymphoma (NHL) with CD 19/ CD 3 bispecific antibody blinatumomab (MT103): Double-step dose increase to continuous infusion of 60 µg/m2/d is tolerable and highly effective", Blood, vol. 116, no. 21, 2010, pages 1186-1187, (B2)

WO-A1-2006/114115 (B2)

CHRISTIAN BRANDL ET AL: "The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 56, no. 10, 20 February 2007 (2007-02-20), pages 1551-1563, XP019539092, SPRINGER, BERLIN, DE ISSN: 1432-0851, DOI: 10.1007/S00262-007-0298-Z (B1)